| Eli Lilly and Company27 programs in shared conditions | 11 · 3 with both in phase 3Breast Neoplasms, Dermatitis, Atopic, Obesity +8 | tersolisib, Imlunestrant, selpercatinib +7 | - Innovent Biologics, Inc.’s mazdutide vs Tirzepatide (US & EU rights: Eli Lilly and Company) (Obesity, NCT07000955)
- Innovent Biologics, Inc.’s IBI3013 in a combination vs baricitinib (US & EU rights: Eli Lilly and Company) (Alopecia Areata, NCT07554222)
- Innovent Biologics, Inc.’s IBI3042 in a combination vs orforglipron (most trials: Eli Lilly and Company) (Obesity, NCT07793019)
|
| Regeneron Pharmaceuticals12 programs in shared conditions | 7 · 2 with both in phase 3Multiple Myeloma, Obesity, Melanoma +4 | fianlimab, cemiplimab, linvoseltamab +1 | - Innovent Biologics, Inc.’s IBI356 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07330934)
- Innovent Biologics, Inc.’s IBI3027 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07754786)
- Innovent Biologics, Inc.’s IBI3002 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07399067)
|
| Sanofi4 programs in shared conditions | 2 · 1 with both in phase 3Dermatitis, Atopic, Carcinoma, Non-Small-Cell Lung | Dupilumab coformulated with berahyaluronidase alfa | - Innovent Biologics, Inc.’s IBI356 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07330934)
- Innovent Biologics, Inc.’s IBI3027 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07754786)
- Innovent Biologics, Inc.’s IBI3002 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07399067)
|
| Jiangsu HengRui Medicine Co., Ltd.46 programs in shared conditions | 17 · 8 with both in phase 3Breast Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms +14 | SHR-1905, HRS-6209, HRS-8080 +6 | - Jiangsu HengRui Medicine Co., Ltd.’s Anti-CTLA-4 Monoclonal Antibody SHR-8068 in a combination vs sintilimab (most trials: Innovent Biologics, Inc.) (Carcinoma, Hepatocellular, NCT06618664)
- Jiangsu HengRui Medicine Co., Ltd.’s HRS-7058 in a combination vs fulzerasib (most trials: Innovent Biologics, Inc.) (Carcinoma, Non-Small-Cell Lung, NCT07601048)
|
| Merck & Co., Inc14 programs in shared conditions | 9 · 1 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Hyperlipoproteinemia Type II +6 | sacituzumab tirumotecan, patritumab deruxtecan, intismeran autogene +5 | - Innovent Biologics, Inc.’s Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Melanoma, NCT06797297)
- Innovent Biologics, Inc.’s Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07122687)
|